What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to furnish a press release, dated March 9, 2020, as an exhibit. This suggests the press release contains information the company deems material enough to disclose via an SEC filing.

Does this 8-K filing contain new financial statements or detailed operational updates?

No, this specific 8-K filing (Item 9.01) primarily lists exhibits. The material information for investors is expected to be found within the press release attached as Exhibit 99.1.

Where can I find the information referenced in this filing?

Investors should locate and review the press release dated March 9, 2020, which is included as Exhibit 99.1 to this Form 8-K filing. This press release will contain the specific details the company is disclosing.

ABBV 8-K SEC Disclosure

Summary

AbbVie Inc. (ABBV) filed a Form 8-K on March 9, 2020, primarily to report the issuance of a press release dated March 9, 2020. While the filing itself does not contain substantial new operational or financial disclosures, the referenced press release likely contains the most pertinent information for investors. Investors should carefully review this press release for any material updates concerning the company's business, financial performance, or strategic initiatives.

Key Highlights

1AbbVie Inc. filed a Form 8-K on March 9, 2020.
2The filing's primary purpose is to provide Exhibit 99.1, a press release dated March 9, 2020.
3No other specific financial statements or material disclosures were included in this 8-K filing itself.
4Investors should seek out and review the press release referenced in Exhibit 99.1 for detailed information.
5The filing also includes Exhibit 104, the Inline XBRL cover page of the report.

AbbVie Inc. 8-K Report, Corporate Update (Mar 9, 2020)

Summary

Key Highlights

Frequently Asked Questions